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Résumé en
anglais
OBJECTIVE: The presence of systemic and/or immune manifestations in
myelodysplasia has been currently reported. The influence of these manifestations
on the natural outcome of myelodysplastic syndrome has to be considered. We
present a multicenter retrospective study (2002-2009) of patients with
myelodysplastic syndrome disclosing systemic and/or immune manifestations.
METHODS: Forty-six patients with myelodysplasia presenting with systemic and/or
immune manifestations were compared in terms of survival with 189 patients with
myelodysplasia lacking these features. RESULTS: The clinical picture in these cases
consisted of fever (13%), arthralgia or arthritis (13%), and cutaneous manifestations
(67%). Four cases of systemic vasculitis have been reported in our series, and they
have a worse prognosis. Immune anomalies were recorded in 29% of the cases, and
the presence of cryoglobulins was also associated with a worse prognosis.
CONCLUSION: A difference in survival between patients with myelodysplastic
syndrome with systemic manifestations and patients lacking these manifestations
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